# The Influencing Factors of 12 Week Efficacy of Polyethylene Glycol Losenatide in Type 2 Diabetes Patients

> **NCT05611684** · PHASE4 · UNKNOWN · sponsor: **Nanjing First Hospital, Nanjing Medical University** · enrollment: 480 (estimated)

## Conditions studied

- Type2 Diabetes Mellitus

## Interventions

- **DRUG:** Polyethylene Glycol Losenatide

## Key facts

- **NCT ID:** NCT05611684
- **Lead sponsor:** Nanjing First Hospital, Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 480 (ESTIMATED)
- **Last updated:** 2022-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05611684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05611684, "The Influencing Factors of 12 Week Efficacy of Polyethylene Glycol Losenatide in Type 2 Diabetes Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05611684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*